Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2005 1
2006 1
2007 1
2010 5
2011 1
2012 1
2013 1
2014 1
2015 1
2018 1
2019 5
2020 2
2021 1
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
Harnessing innate immunity in cancer therapy.
Demaria O, Cornen S, Daëron M, Morel Y, Medzhitov R, Vivier E. Demaria O, et al. Among authors: morel y. Nature. 2019 Oct;574(7776):45-56. doi: 10.1038/s41586-019-1593-5. Epub 2019 Oct 2. Nature. 2019. PMID: 31578484 Review.
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity.
Gauthier L, Morel A, Anceriz N, Rossi B, Blanchard-Alvarez A, Grondin G, Trichard S, Cesari C, Sapet M, Bosco F, Rispaud-Blanc H, Guillot F, Cornen S, Roussel A, Amigues B, Habif G, Caraguel F, Arrufat S, Remark R, Romagné F, Morel Y, Narni-Mancinelli E, Vivier E. Gauthier L, et al. Among authors: morel y. Cell. 2019 Jun 13;177(7):1701-1713.e16. doi: 10.1016/j.cell.2019.04.041. Epub 2019 May 30. Cell. 2019. PMID: 31155232 Free article. Review.
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.
André P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Bléry M, Bonnafous C, Gauthier L, Morel A, Rossi B, Remark R, Breso V, Bonnet E, Habif G, Guia S, Lalanne AI, Hoffmann C, Lantz O, Fayette J, Boyer-Chammard A, Zerbib R, Dodion P, Ghadially H, Jure-Kunkel M, Morel Y, Herbst R, Narni-Mancinelli E, Cohen RB, Vivier E. André P, et al. Among authors: morel y. Cell. 2018 Dec 13;175(7):1731-1743.e13. doi: 10.1016/j.cell.2018.10.014. Epub 2018 Nov 29. Cell. 2018. PMID: 30503213 Free PMC article. Review.
Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant.
Demaria O, Gauthier L, Vetizou M, Blanchard Alvarez A, Vagne C, Habif G, Batista L, Baron W, Belaïd N, Girard-Madoux M, Cesari C, Caratini M, Bosco F, Benac O, Lopez J, Fenis A, Galluso J, Trichard S, Carrette B, Carrette F, Maguer A, Jaubert S, Sansaloni A, Letay-Drouet R, Kosthowa C, Lovera N, Dujardin A, Chanuc F, Le Van M, Bokobza S, Jarmuzynski N, Fos C, Gourdin N, Remark R, Lechevallier E, Fakhry N, Salas S, Deville JL, Le Grand R, Bonnafous C, Vollmy L, Represa A, Carpentier S, Rossi B, Morel A, Cornen S, Perrot I, Morel Y, Vivier E. Demaria O, et al. Among authors: morel y. Cell Rep Med. 2022 Oct 18;3(10):100783. doi: 10.1016/j.xcrm.2022.100783. Cell Rep Med. 2022. PMID: 36260981 Free PMC article.
Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123.
Gauthier L, Virone-Oddos A, Beninga J, Rossi B, Nicolazzi C, Amara C, Blanchard-Alvarez A, Gourdin N, Courta J, Basset A, Agnel M, Guillot F, Grondin G, Bonnevaux H, Bauchet AL, Morel A, Morel Y, Chiron M, Vivier E. Gauthier L, et al. Among authors: morel y. Nat Biotechnol. 2023 Sep;41(9):1296-1306. doi: 10.1038/s41587-022-01626-2. Epub 2023 Jan 12. Nat Biotechnol. 2023. PMID: 36635380 Free PMC article.
[Natural killer cells: promising targets in cancer therapy].
Cornen S, André P, Gauthier L, Morel Y, Vivier É. Cornen S, et al. Among authors: morel y. Med Sci (Paris). 2019 Dec;35(12):990-992. doi: 10.1051/medsci/2019195. Epub 2020 Jan 6. Med Sci (Paris). 2019. PMID: 31903904 Free article. Review. French.
Desirable cell death during anticancer chemotherapy.
Locher C, Conforti R, Aymeric L, Ma Y, Yamazaki T, Rusakiewicz S, Tesnière A, Ghiringhelli F, Apetoh L, Morel Y, Girard JP, Kroemer G, Zitvogel L. Locher C, et al. Among authors: morel y. Ann N Y Acad Sci. 2010 Oct;1209:99-108. doi: 10.1111/j.1749-6632.2010.05763.x. Ann N Y Acad Sci. 2010. PMID: 20958322 Review.
Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis.
Carvelli J, Demaria O, Vély F, Batista L, Chouaki Benmansour N, Fares J, Carpentier S, Thibult ML, Morel A, Remark R, André P, Represa A, Piperoglou C; Explore COVID-19 IPH group; Explore COVID-19 Marseille Immunopole group; Cordier PY, Le Dault E, Guervilly C, Simeone P, Gainnier M, Morel Y, Ebbo M, Schleinitz N, Vivier E. Carvelli J, et al. Among authors: morel y. Nature. 2020 Dec;588(7836):146-150. doi: 10.1038/s41586-020-2600-6. Epub 2020 Jul 29. Nature. 2020. PMID: 32726800 Free PMC article.
Targeting MICA/B with cytotoxic therapeutic antibodies leads to tumor control.
Bléry M, Mrabet-Kraiem M, Morel A, Lhospice F, Bregeon D, Bonnafous C, Gauthier L, Rossi B, Remark R, Cornen S, Anceriz N, Viaud N, Trichard S, Carpentier S, Joulin-Giet A, Grondin G, Liptakova V, Kim Y, Daniel L, Haffner A, Macagno N, Pouyet L, Perrot I, Paturel C, Morel Y, Steinle A, Romagné F, Narni-Mancinelli E, Vivier E. Bléry M, et al. Among authors: morel y. Open Res Eur. 2021 Oct 27;1:107. doi: 10.12688/openreseurope.13314.2. eCollection 2021. Open Res Eur. 2021. PMID: 35967081 Free PMC article.
25 results